Evidence map›Paper›PMID 41301083›Full record

ArticleCancers2025

Niclosamide and Palbociclib Act Synergistically to Reduce Cholangiocarcinoma Cell Viability In Vitro and Inhibit Tumour Growth in a Mouse Model.

Grace Martin, Ka Ying Lee, Christopher Roberts, Jinxia Zheng, Gagan Kaur Batth, William Dalleywater, Farhat Latif Khanim, Sebastian Oltean, Kevin Gaston, Padma-Sheela Jayaraman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Grace MartinSchool of Medicine and Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.
Ka Ying LeeInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Christopher RobertsSchool of Medicine and Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.
Jinxia ZhengDepartment of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter EX1 2LU, UK.
Gagan Kaur BatthSchool of Biomedical Sciences, University of Birmingham, Birmingham B15 2TT, UK.
William DalleywaterSchool of Medicine and Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.
Farhat Latif KhanimSchool of Biomedical Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Sebastian OlteanDepartment of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter EX1 2LU, UK.ORCID 0000-0001-7890-8439
Kevin GastonSchool of Medicine and Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0002-7349-5513
Padma-Sheela JayaramanSchool of Medicine and Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0002-6500-9095

Funding

AMMF 2019/204UK Medical Research Council MR/N012615/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bile ductCDK4/6 inhibitioncholangiocarcinomaniclosamideprimary liver cancer

Identifiers

PMID41301083
PMCPMC12651616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.